Nimer Adeeb1, Christoph J Griessenauer1, Paul M Foreman1, Justin M Moore1, Hussain Shallwani1, Rouzbeh Motiei-Langroudi1, Abdulrahman Alturki1, Adnan H Siddiqui1, Elad I Levy1, Mark R Harrigan1, Christopher S Ogilvy1, Ajith J Thomas2. 1. From the Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (N.A., C.J.G., J.M.M., R.M.-L., A.A., C.S.O., A.J.T.); Department of Neurosurgery, University of Alabama at Birmingham (P.M.F., M.R.H.); and Department of Neurosurgery, State University of New York at Buffalo (H.S., A.H.S., E.I.L.). 2. From the Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (N.A., C.J.G., J.M.M., R.M.-L., A.A., C.S.O., A.J.T.); Department of Neurosurgery, University of Alabama at Birmingham (P.M.F., M.R.H.); and Department of Neurosurgery, State University of New York at Buffalo (H.S., A.H.S., E.I.L.). athomas6@bidmc.harvard.edu.
Abstract
BACKGROUND AND PURPOSE: Thromboembolic complications constitute a significant source of morbidity after neurointerventional procedures. Flow diversion using the pipeline embolization device for the treatment of intracranial aneurysms necessitates the use of dual antiplatelet therapy to reduce this risk. The use of platelet function testing before pipeline embolization device placement remains controversial. METHODS: A retrospective review of prospectively maintained databases at 3 academic institutions was performed from the years 2009 to 2016 to identify patients with intracranial aneurysms treated with pipeline embolization device placement. Clinical and radiographic data were analyzed with emphasis on thromboembolic complications and clopidogrel responsiveness. RESULTS: A total of 402 patients underwent 414 pipeline embolization device procedures for the treatment of 465 intracranial aneurysms. Thromboembolic complications were encountered in 9.2% of procedures and were symptomatic in 5.6%. Clopidogrel nonresponders experienced a significantly higher rate of thromboembolic complications compared with clopidogrel responders (17.4% versus 5.6%). This risk was significantly lower in nonresponders who were switched to ticagrelor when compared with patients who remained on clopidogrel (2.7% versus 24.4%). In patients who remained on clopidogrel, the rate of thromboembolic complications was significantly lower in those who received a clopidogrel boost within 24 hours pre-procedure when compared with those who did not (9.8% versus 51.9%). There was no significant difference in the rate of hemorrhagic complications between groups. CONCLUSIONS: Clopidogrel nonresponders experienced a significantly higher rate of thromboembolic complications when compared with clopidogrel responders. However, this risk seems to be mitigated in nonresponders who were switched to ticagrelor or received a clopidogrel boost within 24 hours pre-procedure.
BACKGROUND AND PURPOSE:Thromboembolic complications constitute a significant source of morbidity after neurointerventional procedures. Flow diversion using the pipeline embolization device for the treatment of intracranial aneurysms necessitates the use of dual antiplatelet therapy to reduce this risk. The use of platelet function testing before pipeline embolization device placement remains controversial. METHODS: A retrospective review of prospectively maintained databases at 3 academic institutions was performed from the years 2009 to 2016 to identify patients with intracranial aneurysms treated with pipeline embolization device placement. Clinical and radiographic data were analyzed with emphasis on thromboembolic complications and clopidogrel responsiveness. RESULTS: A total of 402 patients underwent 414 pipeline embolization device procedures for the treatment of 465 intracranial aneurysms. Thromboembolic complications were encountered in 9.2% of procedures and were symptomatic in 5.6%. Clopidogrel nonresponders experienced a significantly higher rate of thromboembolic complications compared with clopidogrel responders (17.4% versus 5.6%). This risk was significantly lower in nonresponders who were switched to ticagrelor when compared with patients who remained on clopidogrel (2.7% versus 24.4%). In patients who remained on clopidogrel, the rate of thromboembolic complications was significantly lower in those who received a clopidogrel boost within 24 hours pre-procedure when compared with those who did not (9.8% versus 51.9%). There was no significant difference in the rate of hemorrhagic complications between groups. CONCLUSIONS:Clopidogrel nonresponders experienced a significantly higher rate of thromboembolic complications when compared with clopidogrel responders. However, this risk seems to be mitigated in nonresponders who were switched to ticagrelor or received a clopidogrel boost within 24 hours pre-procedure.
Authors: Samuel Pearce; Julian T Maingard; Hong Kuan Kok; Christen D Barras; Jeremy H Russell; Joshua A Hirsch; Ronil V Chandra; Ash Jhamb; Vincent Thijs; Mark Brooks; Hamed Asadi Journal: Clin Neuroradiol Date: 2021-03-01 Impact factor: 3.649
Authors: Mirja M Wirtz; Clemens M Schirmer; Oded Goren; Christian O Bohan; Shamsher Dalal; Gregory Weiner; Paul M Foreman; Christoph J Griessenauer Journal: Interv Neuroradiol Date: 2019-12-19 Impact factor: 1.610
Authors: Mayank Goyal; Kirill Orlov; Mary E Jensen; Allan Taylor; Charles Majoie; Mahesh Jayaraman; Jianmin Liu; Geneviève Milot; Patrick Brouwer; Shinichi Yoshimura; Felipe Albuquerque; Adam Arthur; David Kallmes; Nobuyuki Sakai; Justin F Fraser; Raul Nogueira; Pengfei Yang; Franziska Dorn; Lucie Thibault; Jens Fiehler; René Chapot; Johanna Maria Ospel Journal: Neuroradiology Date: 2020-09-24 Impact factor: 2.804
Authors: Sophia Hohenstatt; Sergio L Vinci; Dominik F Vollherbst; Agostino Tessitore; Niclas Schmitt; Antonio Pitrone; Antonio A Caragliano; Mariano Velo; Markus A Möhlenbruch; Aldo Paolucci Journal: Clin Neuroradiol Date: 2022-06-29 Impact factor: 3.649
Authors: Jodi R DeGrote; Elizabeth M Olafson; Alexander Drofa; Evgueni Kouznetzov; Michael Manchak; Nathan D Leedahl; David D Leedahl Journal: Can J Hosp Pharm Date: 2018-12-31
Authors: Pouya Entezami; Devin N Holden; Alan S Boulos; Alexandra R Paul; Nicholas C Field; Emad Nourollahzadeh; Junichi Yamamoto; John C Dalfino Journal: Interv Neuroradiol Date: 2020-07-01 Impact factor: 1.610
Authors: Sami Al Kasab; Waldo R Guerrero; Daichi Nakagawa; Edgar A Samaniego; Santiago Ortega-Gutierrez; David Hasan Journal: Interv Neurol Date: 2019-01-16
Authors: Li-Mei Lin; Bowen Jiang; Jessica K Campos; Narlin B Beaty; Matthew T Bender; Rafael J Tamargo; Judy Huang; Geoffrey P Colby; Alexander L Coon Journal: Interv Neurol Date: 2018-02-27